Antibiotics Are Man's Greatest Invention

Antibiotics Currently in Global Clinical Development

For definitions of drug development terms, visit: https://www.pewtrusts.org/en/research-and-analysis/articles/2014/03/12/glossary-for-the-antibiotic-pipeline.

Note: The following drugs have been removed from the pipeline. Removed candidates will be included in future updates if development resumes. In the case of the September 2017 update, candidates were added to reflect the expanded global scope of the pipeline.

June 2019 review: AIC499 was removed during the June 2019 review because there was direct communication from the company regarding the termination of development.

December 2018 review: No changes.

June 2018 review: Cadazolid, DS-2969, GSK3342830, and Zabofloxacin were removed during the June 2018 review. These drugs were either no longer included in the research and development pipelines on the company website, or there was direct communication from the company regarding the status of the drugs.

September 2017 review: The antibiotics pipeline was expanded to include global development. With the expanded global methodology, the following antibiotics were added: lascufloxacin, AIC499, and AAI-101. Ramoplanin and TD-1607 were removed during the September 2017 review because they were no longer included in the research and development pipelines on the company’s website. Aztreonam + Avibactam was removed from the pipeline because avibactam is an approved beta-lactamase inhibitor.

March 2017 review: Ceftaroline + Avibactam was removed during the March 2017 review because it was no longer included in the research and development pipelines on the company’s website.

September 2016 review: BAL30072 was removed during the September 2016 review because it was no longer included in the research and development pipelines on the company website.

March 2016 review: Radezolid, Debio 1452, avarofloxacin, and surotomycin were removed during the March 2016 review. Radezolid was removed because systemic indications for this product were no longer included in the development plans listed on the sponsor website. Debio 1452, avarofloxacin, and surotomycin were no longer included in the research and development pipelines on the company website.

September 2015 review: No changes.

March 2015 review: No changes.

December 2014 review: EDP-788 (Enanta Pharmaceuticals) and TD-1792 (Theravance Biopharma) were removed during the December 2014 review. These drugs were either no longer included in the research and development pipelines on the company website, or there was direct communication from the company regarding the status of the drugs. Additionally, GSK-2696266, which had been removed during the September 2014 review, is included in this pipeline again as S-649266, which is being developed by Shionogi.

September 2014 review: GSK-2696266 and GSK-1322322 (GlaxoSmithKline), ACHN-975 (Achaogen), and LFF571 (Novartis) were removed during the September 2014 review. These drugs were either no longer included in the research and development pipelines on the company website, or there was direct communication from the company regarding the status of the drugs.

June 2014 review: Ceftobiprole, an antibiotic developed by Basilea Pharmaceutica, had been included in our analysis; however, the company announced in June 2014 that it is not pursuing further development in the United States until a partner has been acquired. As of April 2016, Basilea announced a partnership with BARDA for Phase 3 development of ceftobiprole in the United States.

* Michael Hay et al., “Clinical Development Success Rates for Investigational Drugs,” Nature Biotechnology 32, no. 1 (2014): 40–51, https://www.ncbi.nlm.nih.gov/pubmed/2440692.

Source